1
6
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T61621 | IMMH001 | ||
IMMH001, also known as SYL930, is an orally active compound that exhibits potent selectivity as an agonist for the S1P1 receptor, which is the sphingosine-1-phosphate receptor 1. This compound effectively reduces the lev... |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-04037 | MIP-1 alpha/CCL3 Protein, Rat, Recombinant | Rat | E. coli |
MIP-1 alpha/CCL3 Protein, Rat, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 7.8 kDa and the accession number is P50229. | |||
TMPY-00649 | MIP-1 alpha/CCL3 Protein, Human, Recombinant (His) | Human | P. pastoris (Yeast) |
MIP-1 alpha/CCL3 Protein, Human, Recombinant (His) is expressed in yeast with His tag. The predicted molecular weight is 9.2 kDa and the accession number is A0N0R1. | |||
TMPJ-00005 | CCL3 Protein, Human, Recombinant | Human | E. coli |
Human Chemokine (C-C Motif) Ligand 3 (CCL3) is a small cytokine belonging to the CC chemokine family. CCL3 is primarily expressed in T cells, B cells, and monocytes after antigen or mitogen stimulation. CCL3 exhibits che... | |||
TMPJ-00831 | CCL3 Protein, Mouse, Recombinant (His) | Mouse | E. coli |
C-C Motif Chemokine 3 (MIP-1 alpha,CCL3 ) is a member of the beta or CC subfamily of chemokines and is closely related to CCL4/MIP-1 beta. CCL3 expression can be induced in a variety of hematopoietic cells, fibroblasts, ... | |||
TMPY-03231 | MIP-1 alpha/CCL3 Protein, Mouse, Recombinant | Mouse | E. coli |
MIP-1 alpha/CCL3 Protein, Mouse, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 8.01 kDa and the accession number is P10855. | |||
TMPJ-00873 | CCL3L1 Protein, Human, Recombinant (His) | Human | HEK293 Cells |
C-C Motif Chemokine 3-Like 1 (CCL3L1) is a secreted protein that belongs to the intercrine beta (chemokine CC) family. CCL3L1 is a ligand for CCR1, CCR3 and CCR5. CCL3L1 binds to several chemokine receptors including che... |